Quarterly report [Sections 13 or 15(d)]

Stockholders??? Equity (Details Narrative)

v3.25.3
Stockholders’ Equity (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Jun. 12, 2025
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Nov. 26, 2024
Sep. 30, 2023
Oct. 03, 2022
Jul. 23, 2021
Defined Benefit Plan Disclosure [Line Items]                    
Outstanding warrants to purchase an aggregate shares   56,237   56,237   56,237        
Grant option acquire common shares 2,800,000                  
Exercise price $ 0.12                  
Grant-date fair value       $ 188,761            
Director [Member]                    
Defined Benefit Plan Disclosure [Line Items]                    
Shares remaining available for grant   100,434   100,434            
Twin Vee [Member]                    
Defined Benefit Plan Disclosure [Line Items]                    
Stock based compensation expense   $ 63,897 $ 278,867 $ 179,493 $ 1,022,894          
Dividend yield       0.00%            
Options unvested       105,211            
Exercise price     $ 41.61   $ 41.61     $ 35.17    
Grant-date fair value       $ 98,371 $ 233,957          
Twin Vee [Member] | Common Stock Warrants [Member] | Underwriters [Member]                    
Defined Benefit Plan Disclosure [Line Items]                    
Warrants outstanding             10,550   14,375 15,000
Warrants weighted-average exercise             $ 102.20   $ 34.38 $ 75.00
Expire date             August 11, 2027   September 28, 2027 July 20, 2026
Twin Vee [Member] | Common Stock Warrants One [Member] | Underwriters [Member]                    
Defined Benefit Plan Disclosure [Line Items]                    
Warrants outstanding             16,312      
Warrants weighted-average exercise             $ 30.70      
Expire date             June 12, 2028